Adenosine News and Research

RSS

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ß-N9-glycosidic bond.

Study shows new RNA letter as regulatory key to control gene expression

DNA, RNA, protein -- the end. Or is it? Until recently, the pattern used to encode genetic information into our cells was considered to be relatively straightforward: four letters (A,G,C,T) for DNA and four (A,G,C,U) for RNA. This equation, however, turned out to be oversimplified -- RNA was holding out.

17 Feb 2016

Research: Adenosine deaminase may help activate immune system against HIV

New research findings published in the February 2016 issue of the Journal of Leukocyte Biology, suggest that a new therapeutic strategy for HIV may already be available by repurposing an existing prescription drug.

3 Feb 2016

Researchers reveal specific enzyme responsible for sensing energy source that fuels growth of cancer cells

An international research team formed by a University of Cincinnati cancer researcher has shown for the first time that a specific enzyme is responsible for sensing the available supply of GTP, an energy source that fuels the uncontrolled growth of cancer cells. The research underscores the enzyme's potential to become a therapeutic target for future cancer drugs.

11 Jan 2016

Antiscarring paste can halt fibrosis caused by radiation treatment

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB.

5 Jan 2016

Study on myosins may lead to therapies for muscle diseases, cancers

Understanding how tiny molecular motors called myosins use energy to fuel biological tasks like contracting muscles could lead to therapies for muscle diseases and cancers, says a team of researchers led by Penn State College of Medicine scientists.

22 Dec 2015

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants.

13 Dec 2015

New technique could improve heart scans for patients

A team of Oxford University researchers has developed a technique that could improve heart scans for patients, giving more information about the heart than traditional scans and without any injections, making them safer and faster.

10 Dec 2015

Tetra begins human Phase 1 safety trials of BPN14770

Tetra Discovery Partners today announced that the company has initiated human Phase 1 safety trials of its lead compound BPN14770, which Tetra is developing as a potential treatment to both improve memory and slow the progression of Alzheimer's disease.

9 Dec 2015

Scientists reveal why loss of CD73 enzyme in human cancer promotes tumor progression

Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression.

8 Dec 2015

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.

7 Dec 2015

New hope for patients with Duchenne muscular dystrophy

New hope for Duchenne muscular dystrophy (DMD) patients. A mouse genetic study in PLoS Medicine reports that targeting the P2RX7 gene, a purinoreceptor, may halt the progression of DMD.

14 Oct 2015

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.

12 Oct 2015

New data analysis platform reveals major flaw in GC-MS process

A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.

7 Oct 2015

Study finds no significant impact of ATP on reducing late recurrence of AF

Late recurrence of atrial fibrillation (AF) is not reduced in patients whose pulmonary vein isolation (PVI) treatment incorporates the addition of adenosine triphosphate (ATP), according to results of the UNDER-ATP trial.

31 Aug 2015

Simple modification can increase effectiveness of emergency treatment for patients with supraventricular tachycardia

A simple, safe and cost-free modification to a physical technique used to treat patients in the emergency department with an abnormally fast heart rhythm could improve its effectiveness by more than a quarter, according to a study published in The Lancet today (25 August 2015).

26 Aug 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Common gout medications may offer protection from alcohol-induced liver disease, inflammation

New research in mice shows that two commonly used gout medications, which target uric acid and adenosine triphosphate, may offer protection from alcohol-induced liver disease and inflammation.

3 Aug 2015

Study sheds light on certain antagonist drugs that block physiological responses

Members of the Consolidated Research Group of Molecular Neurobiology of the Department of Biochemistry and Molecular Biology of the University of Barcelona (UB), affiliated with the Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), have published a study in the journal Proceedings of the National Academy of Sciences (PNAS) about the formation of G protein-coupled receptors (GPCRs) which allows understanding the unexpected behaviour of some antagonists that block physiological responses.

30 Jul 2015

New study estimates link between coffee consumption habits and incidence of mild cognitive impairment

A new study by researchers at the University of Bari Aldo Moro, Bari, Italy, Geriatric Unit & Laboratory of Gerontology and Geriatrics, IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy, and Istituto Superiore di Sanità, Roma, Italy, estimates the association between change or constant habits in coffee consumption and the incidence of mild cognitive impairment (MCI), evaluating 1,445 individuals recruited from 5,632 subjects, aged 65-84 year old, from the Italian Longitudinal Study on Aging (ILSA), a population-based sample from eight Italian municipalities with a 3.5-year median follow-up.

29 Jul 2015